Name | Number of supported studies | Average coverage | |
---|---|---|---|
CD8-positive, alpha-beta T cell | 40 studies | 58% ± 16% | |
T cell | 23 studies | 35% ± 14% | |
natural killer cell | 18 studies | 24% ± 7% | |
mucosal invariant T cell | 16 studies | 45% ± 17% | |
mature NK T cell | 14 studies | 39% ± 13% | |
naive thymus-derived CD8-positive, alpha-beta T cell | 14 studies | 65% ± 16% | |
CD8-positive, alpha-beta memory T cell | 13 studies | 70% ± 15% | |
gamma-delta T cell | 13 studies | 27% ± 7% | |
effector memory CD8-positive, alpha-beta T cell | 12 studies | 63% ± 22% | |
CD16-positive, CD56-dim natural killer cell, human | 10 studies | 25% ± 8% | |
effector CD8-positive, alpha-beta T cell | 9 studies | 59% ± 22% | |
central memory CD8-positive, alpha-beta T cell | 5 studies | 63% ± 23% | |
effector memory CD8-positive, alpha-beta T cell, terminally differentiated | 5 studies | 46% ± 17% | |
exhausted T cell | 5 studies | 69% ± 23% | |
CD16-negative, CD56-bright natural killer cell, human | 4 studies | 28% ± 9% | |
leukocyte | 3 studies | 41% ± 15% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 9 studies | 18% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 1102.63 | 578 / 578 | 87% | 18.68 | 1002 / 1155 |
thymus | 97% | 516.87 | 633 / 653 | 75% | 81.01 | 453 / 605 |
prostate | 92% | 380.80 | 226 / 245 | 68% | 6.92 | 339 / 502 |
stomach | 92% | 622.06 | 331 / 359 | 64% | 13.31 | 182 / 286 |
uterus | 80% | 206.95 | 136 / 170 | 71% | 18.41 | 327 / 459 |
breast | 72% | 296.41 | 330 / 459 | 79% | 16.26 | 884 / 1118 |
intestine | 64% | 529.95 | 618 / 966 | 61% | 9.07 | 324 / 527 |
kidney | 52% | 165.58 | 46 / 89 | 71% | 28.17 | 641 / 901 |
pancreas | 51% | 96.07 | 168 / 328 | 70% | 12.37 | 125 / 178 |
esophagus | 62% | 155.11 | 901 / 1445 | 55% | 7.84 | 101 / 183 |
bladder | 52% | 496.05 | 11 / 21 | 56% | 9.84 | 283 / 504 |
brain | 91% | 309.75 | 2413 / 2642 | 16% | 1.41 | 116 / 705 |
skin | 36% | 67.93 | 643 / 1809 | 72% | 36.12 | 338 / 472 |
liver | 68% | 144.80 | 154 / 226 | 34% | 6.21 | 137 / 406 |
spleen | 100% | 9996.58 | 241 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 96.66 | 28 / 29 |
tonsil | 0% | 0 | 0 / 0 | 91% | 36.44 | 41 / 45 |
ovary | 33% | 72.71 | 59 / 180 | 52% | 6.19 | 222 / 430 |
adipose | 84% | 367.13 | 1009 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 83% | 4120.36 | 775 / 929 | 0% | 0 | 0 / 0 |
adrenal gland | 58% | 114.22 | 149 / 258 | 23% | 2.14 | 54 / 230 |
blood vessel | 49% | 162.05 | 651 / 1335 | 0% | 0 | 0 / 0 |
heart | 31% | 59.86 | 270 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 25% | 7.32 | 20 / 80 |
muscle | 2% | 3.29 | 16 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007169 | Biological process | cell surface receptor protein tyrosine kinase signaling pathway |
GO_0050852 | Biological process | T cell receptor signaling pathway |
GO_0006955 | Biological process | immune response |
GO_0002250 | Biological process | adaptive immune response |
GO_0019882 | Biological process | antigen processing and presentation |
GO_0002456 | Biological process | T cell mediated immunity |
GO_0042110 | Biological process | T cell activation |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0045065 | Biological process | cytotoxic T cell differentiation |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0043235 | Cellular component | receptor complex |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0044853 | Cellular component | plasma membrane raft |
GO_0042101 | Cellular component | T cell receptor complex |
GO_0015026 | Molecular function | coreceptor activity |
GO_0023024 | Molecular function | MHC class I protein complex binding |
GO_0042288 | Molecular function | MHC class I protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | CD8A |
Protein name | T-cell surface glycoprotein CD8 alpha chain T-cell surface glycoprotein CD8 alpha chain (T-lymphocyte differentiation antigen T8/Leu-2) (CD antigen CD8a) |
Synonyms | hCG_34192 MAL |
Description | FUNCTION: Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. In T-cells, functions primarily as a coreceptor for MHC class I molecule:peptide complex. The antigens presented by class I peptides are derived from cytosolic proteins while class II derived from extracellular proteins. Interacts simultaneously with the T-cell receptor (TCR) and the MHC class I proteins presented by antigen presenting cells (APCs). In turn, recruits the Src kinase LCK to the vicinity of the TCR-CD3 complex. LCK then initiates different intracellular signaling pathways by phosphorylating various substrates ultimately leading to lymphokine production, motility, adhesion and activation of cytotoxic T-lymphocytes (CTLs). This mechanism enables CTLs to recognize and eliminate infected cells and tumor cells. In NK-cells, the presence of CD8A homodimers at the cell surface provides a survival mechanism allowing conjugation and lysis of multiple target cells. CD8A homodimer molecules also promote the survival and differentiation of activated lymphocytes into memory CD8 T-cells. . |
Accessions | P01732 ENST00000409781.1 ENST00000699439.1 [P01732-2] Q8TAW8 B8ZZZ4 ENST00000283635.8 [P01732-1] ENST00000352580.7 [P01732-2] Q96QR6 ENST00000409511.6 [P01732-1] |